このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

新たに診断された子宮内膜がんの参加者における治癒目的の手術後の放射線療法を伴うまたは伴わない補助化学療法と組み合わせたペムブロリズマブ(MK-3475)の研究(MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

2026年9月17日 更新者:Merck Sharp & Dohme LLC

治癒を目的とした手術後の新たに診断された高リスク子宮内膜がんの治療のための放射線療法を伴うまたは伴わない補助化学療法と組み合わせたペムブロリズマブ対プラセボの第3相無作為化二重盲検試験(KEYNOTE-B21 / ENGOT-en11 / GOG- 3053)

The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to OS.

調査の概要

研究の種類

介入

入学 (推定)

990

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35249
        • University of Alabama - Birmingham ( Site 3061)
      • Mobile、Alabama、アメリカ、36604
        • University of South Alabama, Mitchell Cancer Institute ( Site 3058)
    • Arizona
      • Phoenix、Arizona、アメリカ、85016
        • HonorHealth Research Institute - Biltmore ( Site 3043)
      • Tucson、Arizona、アメリカ、85711
        • Arizona Oncology Associates PC- HOPE ( Site 3049)
    • California
      • La Jolla、California、アメリカ、92093-0698
        • UCSD Moores Cancer Center ( Site 3053)
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • University Of Colorado ( Site 3051)
    • Connecticut
      • New Haven、Connecticut、アメリカ、06511
        • Smilow Cancer Hospital at Yale New Haven ( Site 3070)
    • Florida
      • Miami Beach、Florida、アメリカ、33140
        • Mount Sinai Cancer Center ( Site 3081)
    • Georgia
      • Atlanta、Georgia、アメリカ、30342
        • Northside Hospital ( Site 3036)
    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • Northwestern Memorial Hospital ( Site 3044)
    • Indiana
      • Fort Wayne、Indiana、アメリカ、46845
        • Parkview Cancer Institute ( Site 3067)
      • Indianapolis、Indiana、アメリカ、46202
        • Indiana University Melvin and Bren Simon Cancer Center ( Site 3071)
    • Iowa
      • Iowa City、Iowa、アメリカ、52242
        • University of Iowa Hospital and Clinics ( Site 3046)
    • Kentucky
      • Louisville、Kentucky、アメリカ、40207
        • Norton Cancer Institute - St. Matthews ( Site 3056)
    • Louisiana
      • Shreveport、Louisiana、アメリカ、71103
        • WK Physicians Network/Gynecologic Oncology Associates ( Site 3047)
    • Massachusetts
      • Worcester、Massachusetts、アメリカ、01605
        • University of Massachusetts Medical School-Division of Gynecologic Oncology ( Site 3037)
    • New York
      • Mineola、New York、アメリカ、11501
        • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 3076)
      • New York、New York、アメリカ、10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 3042)
      • The Bronx、New York、アメリカ、10461
        • Montefiore Medical Center ( Site 3065)
    • North Carolina
      • Durham、North Carolina、アメリカ、27710
        • Duke Cancer Center ( Site 3072)
    • North Dakota
      • Fargo、North Dakota、アメリカ、58102
        • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 3080)
    • Ohio
      • Columbus、Ohio、アメリカ、43210
        • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 3066)
    • Oregon
      • Portland、Oregon、アメリカ、97210
        • Legacy Good Samaritan Medical Center ( Site 3033)
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19107
        • Sidney Kimmel Cancer Center - Jefferson Health ( Site 3078)
      • Pittsburgh、Pennsylvania、アメリカ、15224
        • AHN West Penn Hospital ( Site 3060)
      • Willow Grove、Pennsylvania、アメリカ、19090
        • Abington Hospital - Asplundh Cancer Center ( Site 3073)
    • South Dakota
      • Sioux Falls、South Dakota、アメリカ、57104
        • Sanford Gynecology Oncology ( Site 3045)
    • Texas
      • Dallas、Texas、アメリカ、75390
        • UT Southwestern Medical Center ( Site 3063)
    • Virginia
      • Richmond、Virginia、アメリカ、23298
        • VCU Massey Cancer Center ( Site 3068)
      • Buenos Aires、アルゼンチン、C1012AAR
        • IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas ( Site 1010)
      • Buenos Aires、アルゼンチン、C1118AAT
        • Hospital Aleman ( Site 1001)
      • La Rioja、アルゼンチン、F5300COE
        • Centro Oncologico Riojano Integral ( Site 1007)
    • Buenos Aires
      • Berazategui、Buenos Aires、アルゼンチン、B1884BBF
        • Centro de Oncología e Investigación de Buenos Aires ( Site 1005)
      • CABA、Buenos Aires、アルゼンチン、C1012AAR
        • IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 1006)
      • CABA、Buenos Aires、アルゼンチン、C1431FWO
        • CEMIC ( Site 1009)
      • Ciudad Autónoma de Buenos Aires、Buenos Aires、アルゼンチン、C1280AEB
        • Hospital Britanico de Buenos Aires ( Site 1002)
      • Mar del Plata、Buenos Aires、アルゼンチン、B7600FZO
        • Instituto de Investigaciones Clinicas Mar del Plata ( Site 1003)
    • Santa Fe Province
      • Rosario、Santa Fe Province、アルゼンチン、S2000KZE
        • Instituto de Oncologia de Rosario ( Site 1004)
      • Leicester、イギリス、LE1 5WW
        • Leicester Royal Infirmary. Univ. Hosp. of Leicester NHS Trust ( Site 2249)
      • Manchester、イギリス、M20 4BX
        • The Christie Hospital NHS Foundation Trust ( Site 2243)
    • Bristol, City of
      • Bristol、Bristol, City of、イギリス、BS2 8ED
        • Bristol Haematology and Oncology Centre ( Site 2244)
    • East Riding Of Yorkshire
      • Cottingham、East Riding Of Yorkshire、イギリス、HU165JQ
        • Castle Hill Hospital-Academic Oncology ( Site 2252)
    • Glasgow City
      • Glasgow、Glasgow City、イギリス、G12 0YN
        • Beatson West of Scotland Cancer Centre ( Site 2247)
    • London, City of
      • London、London, City of、イギリス、NW1 2PG
        • UCLH NHS Foundation Trust ( Site 2242)
      • London、London, City of、イギリス、SW3 6JJ
        • Royal Marsden NHS Foundation Trust ( Site 2248)
      • Sutton、London, City of、イギリス、SM2 5PT
        • Royal Marsden Hospital Sutton-Surrey ( Site 2241)
      • Haifa、イスラエル、3525408
        • Rambam Medical Center ( Site 2307)
      • Holon、イスラエル、5810001
        • Edith Wolfson Medical Center ( Site 2306)
      • Jerusalem、イスラエル、9112001
        • Hadassah Medical Center. Ein Kerem ( Site 2303)
      • Petah Tikva、イスラエル、4941492
        • Rabin Medical Center ( Site 2305)
      • Ramat Gan、イスラエル、5265601
        • Chaim Sheba Medical Center ( Site 2301)
      • Brescia、イタリア、25123
        • Azienda Ospedaliera Spedali Civili di Brescia ( Site 2135)
      • Milan、イタリア、20132
        • IRCCS Ospedale San Raffaele ( Site 2130)
      • Milan、イタリア、20141
        • Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 2132)
      • Naples、イタリア、80131
        • Azienda Ospedaliera Universitaria Federico II ( Site 2123)
      • Naples、イタリア、80131
        • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 2127)
      • Padova、イタリア、35128
        • Istituto Oncologico Veneto IRCCS-Oncologia 2 ( Site 2134)
    • Abruzzo
      • Roma、Abruzzo、イタリア、00144
        • Istittuto Nazionale dei Tumori Regina Elena IRCCS - IFO ( Site 2121)
    • Lazio
      • Rome、Lazio、イタリア、00168
        • Fondazione Policlinico Universitario Agostino Gemelli ( Site 2124)
    • Lombardy
      • Milan、Lombardy、イタリア、20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 2122)
    • Piedmont
      • Candiolo、Piedmont、イタリア、10060
        • INOC - Istituto Nazionale Oncologico Candiolo ( Site 2125)
    • Chernihiv Oblast
      • Chernihiv、Chernihiv Oblast、ウクライナ、14029
        • Chernihiv Medical Center of Modern Oncology ( Site 2368)
    • Chernivetska Oblast
      • Chernivtsi、Chernivetska Oblast、ウクライナ、58013
        • Municipal Enterprise "Bukovinian сlinical oncology сenter" ( Site 2366)
    • Kharkiv Oblast
      • Kharkiv、Kharkiv Oblast、ウクライナ、61024
        • SO Grigoriev Institute for Medical Radiology and Oncology of NAMS of Ukraine ( Site 2363)
    • Khmelnytskyi Oblast
      • Khmelnitskyi、Khmelnytskyi Oblast、ウクライナ、29009
        • MNE "Khmelnytskyi regional antitumor center" ( Site 2365)
    • Kyivska Oblast
      • Kiev、Kyivska Oblast、ウクライナ、08720
        • LISOD - Israeli Oncological Hospital MedX-ray International Group LLC ( Site 2364)
    • Lviv Oblast
      • Lviv、Lviv Oblast、ウクライナ、79031
        • Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 2361)
    • Volyn Oblast
      • Lutsk、Volyn Oblast、ウクライナ、43018
        • Volyn Regional Clinical Hospital Regional Medical Oncology Centre ( Site 2362)
    • Styria
      • Graz、Styria、オーストリア、8036
        • Medizinische Universitat Graz ( Site 2004)
    • Tyrol
      • Innsbruck、Tyrol、オーストリア、6020
        • Medizinische Universitaet Innsbruck ( Site 2001)
    • Alberta
      • Calgary、Alberta、カナダ、T2N 5G2
        • Arthur J.E. Child Comprehensive Cancer Centre ( Site 3007)
    • Ontario
      • Kingston、Ontario、カナダ、K7L 2V7
        • Kingston Health Sciences Centre ( Site 3003)
    • Quebec
      • Montreal、Quebec、カナダ、H2X 0C1
        • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 3006)
      • Montreal、Quebec、カナダ、H4A 3J1
        • McGill University Health Centre ( Site 3005)
      • Québec、Quebec、カナダ、G1J 1Z4
        • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 3002)
      • Thessaloniki、ギリシャ、546 45
        • Euromedica General Clinic of Thessaloniki ( Site 2422)
    • Achaia
      • Pátrai、Achaia、ギリシャ、263 35
        • General Hospital of Patras. St Andrews ( Site 2421)
    • Attica
      • Athens、Attica、ギリシャ、115 28
        • Geniko Panepistimako Nosokomeio ARETEIO ( Site 2423)
      • Athens、Attica、ギリシャ、115 28
        • Perifereiako Geniko Nosokomeio ALEXANDRA ( Site 2425)
      • Chaïdári、Attica、ギリシャ、124 62
        • Athens University Hospital ATTIKON ( Site 2424)
      • Marousi、Attica、ギリシャ、151 23
        • Hospital Hygeia ( Site 2426)
    • Antioquia
      • Medellín、Antioquia、コロンビア、050030
        • Fundacion Colombiana de Cancerología Clinica Vida ( Site 1096)
    • Bogota D.C.
      • Bogotá、Bogota D.C.、コロンビア、111511
        • Instituto Nacional de Cancerología E.S.E ( Site 1094)
    • Departamento de Nariño
      • Pasto、Departamento de Nariño、コロンビア、520002
        • Instituto Cancerologico de Nariño S.A.S. ( Site 1092)
    • Valle del Cauca Department
      • Cali、Valle del Cauca Department、コロンビア、760032
        • Fundación Valle del Lili ( Site 1093)
    • Stockholm County
      • Solna、Stockholm County、スウェーデン、171 76
        • Karolinska Universitetssjukhuset Solna ( Site 2220)
    • Uppsala County
      • Uppsala、Uppsala County、スウェーデン、751 85
        • Blod-och Tumorsjukdomar ( Site 2221)
    • Östergötland County
      • Linköping、Östergötland County、スウェーデン、581 85
        • Universitetssjukhuset i Linkoping. ( Site 2222)
      • Barcelona、スペイン、08035
        • Hospital Vall D Hebron ( Site 2182)
      • Barcelona、スペイン、08036
        • Hospital Clinic i Provincial ( Site 2185)
      • Córdoba、スペイン、14004
        • Hospital Universitario Reina Sofia ( Site 2183)
      • Madrid、スペイン、28040
        • Hospital Clinico San Carlos ( Site 2187)
      • Madrid、スペイン、28046
        • Hospital Universitario La Paz ( Site 2186)
    • Gerona
      • Girona、Gerona、スペイン、17007
        • Institut Català d'Oncologia (ICO) - Girona ( Site 2184)
    • Madrid, Comunidad de
      • Madrid、Madrid, Comunidad de、スペイン、28027
        • Clinica Universitaria de Navarra ( Site 2181)
      • Olomouc、チェコ、77900
        • Fakultni nemocnice Olomouc ( Site 2392)
    • Brno-mesto
      • Brno、Brno-mesto、チェコ、62500
        • Fakultní nemocnice Brno Bohunice-Gynekologicko-porodnicka klinika ( Site 2394)
    • Praha 10
      • Prague、Praha 10、チェコ、100 34
        • Fakultni nemocnice Kralovske Vinohrady ( Site 2393)
    • Praha 2
      • Prague、Praha 2、チェコ、128 08
        • Vseobecna fakultni nemocnice v Praze ( Site 2391)
    • Araucania
      • Temuco、Araucania、チリ、4800827
        • Centro Investigación del Cáncer James Lind ( Site 1061)
    • Region M. de Santiago
      • Santiago、Region M. de Santiago、チリ、7500921
        • Fundacion Arturo Lopez Perez FALP ( Site 1062)
      • Santiago、Region M. de Santiago、チリ、8330032
        • Centro de Cancer Nuestra Senora de la Esperanza ( Site 1063)
      • Santiago、Region M. de Santiago、チリ、8420383
        • Bradfordhill-Clinical Area ( Site 1070)
    • Valparaiso
      • Viña del Mar、Valparaiso、チリ、2520598
        • Oncocentro ( Site 1065)
    • Capital Region
      • Copehagen、Capital Region、デンマーク、2100
        • Rigshospitalet University Hospital ( Site 2515)
      • Herlev、Capital Region、デンマーク、2730
        • Herlev Hospital ( Site 2514)
    • North Denmark
      • Aalborg、North Denmark、デンマーク、9100
        • Aalborg Universitetshospital ( Site 2511)
    • Region Sjælland
      • Roskilde、Region Sjælland、デンマーク、4000
        • Roskilde Sygehus ( Site 2513)
    • Region Syddanmark
      • Odense、Region Syddanmark、デンマーク、5000
        • Odense Universitetshospital ( Site 2512)
      • Adana、トルコ(Türkiye)、01250
        • Baskent Adana Dr Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 2355)
      • Adana、トルコ(Türkiye)、01330
        • Cukurova Uni. Tip Fakultesi ( Site 2353)
      • Ankara、トルコ(Türkiye)、06490
        • Baskent Universitesi Ankara Hastanesi ( Site 2354)
      • Ankara、トルコ(Türkiye)、06590
        • Ankara Universitesi Tıp Fakultesi Hastanesi ( Site 2350)
      • Istanbul、トルコ(Türkiye)、34214
        • Medipol Universite Hastanesi ( Site 2352)
      • Izmir、トルコ(Türkiye)、35100
        • Ege University Medical Faculty ( Site 2351)
      • Izmir、トルコ(Türkiye)、35575
        • I.E.U. Medical Point Hastanesi ( Site 2356)
    • Baden-Wurttemberg
      • Heilbronn、Baden-Wurttemberg、ドイツ、74078
        • SLK-Kliniken Heilbronn GmbH ( Site 2116)
      • Ludwigsburg、Baden-Wurttemberg、ドイツ、71640
        • Klinikum Ludwigsburg ( Site 2111)
      • Tübingen、Baden-Wurttemberg、ドイツ、72076
        • Universitaetsklinikum Tuebingen ( Site 2113)
    • Lower Saxony
      • Hanover、Lower Saxony、ドイツ、30625
        • Medizinische Hochschule Hannover-Department of Obstetrics and Gynecology ( Site 2109)
    • North Rhine-Westphalia
      • Bonn、North Rhine-Westphalia、ドイツ、53127
        • Universitätsklinikum Bonn-Gynaecological oncology ( Site 2103)
      • Essen、North Rhine-Westphalia、ドイツ、45136
        • Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung ( Site 2105)
    • Saxony
      • Dresden、Saxony、ドイツ、01307
        • Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur ( Site 2104)
    • Schleswig-Holstein
      • Lübeck、Schleswig-Holstein、ドイツ、23538
        • Universitätsklinikum Schleswig-Holstein ( Site 2101)
      • Oslo、ノルウェー、0310
        • Oslo Universitetssykehus Radiumhospitalet ( Site 2151)
    • Troms
      • Tromsø、Troms、ノルウェー、9019
        • University Hospital of North Norway ( Site 2153)
    • Vest-Agder
      • Kristiansand、Vest-Agder、ノルウェー、4615
        • Soerlandet sykehus HF Kristiansand ( Site 2152)
    • Northern Savonia
      • Kuopio、Northern Savonia、フィンランド、70210
        • Kuopio University Hospital ( Site 2543)
    • Pirkanmaa
      • Tampere、Pirkanmaa、フィンランド、33520
        • Tampere University Hospital ( Site 2541)
    • Southwest Finland
      • Turku、Southwest Finland、フィンランド、20520
        • Turku University Hospital ( Site 2542)
    • Ain
      • Vandœuvre-lès-Nancy、Ain、フランス、54519
        • Institut De Cancerologie De Lorraine ( Site 2072)
    • Alpes-Maritimes
      • Nice、Alpes-Maritimes、フランス、06189
        • Centre Antoine Lacassagne ( Site 2073)
    • Calvados
      • Caen、Calvados、フランス、14076
        • Centre Francois Baclesse ( Site 2062)
    • Cotes-d Armor
      • Plérin、Cotes-d Armor、フランス、22190
        • Hôpital Privé Des Côtes d'Armor ( Site 2063)
    • Doubs
      • Besançon、Doubs、フランス、25000
        • CHU Besancon - Hopital Jean Minjoz ( Site 2068)
    • Gironde
      • Bordeaux、Gironde、フランス、33076
        • Institut Bergonie ( Site 2067)
    • Haute-Garonne
      • Toulouse、Haute-Garonne、フランス、31059
        • Institut Universitaire du Cancer Toulouse - Oncopole ( Site 2065)
    • Herault
      • Montpellier、Herault、フランス、34298
        • Institut Regional du Cancer de Montpellier - ICM ( Site 2069)
    • Loire-Atlantique
      • Nantes、Loire-Atlantique、フランス、44277
        • Hopital prive du Confluent ( Site 2061)
    • Rhone
      • Pierre-Bénite、Rhone、フランス、69310
        • Centre Hospitalier Lyon Sud ( Site 2064)
    • Île-de-France Region
      • Paris、Île-de-France Region、フランス、75014
        • Hopital Cochin ( Site 2070)
      • Villejuif、Île-de-France Region、フランス、94805
        • Gustave Roussy ( Site 2071)
      • Liège、ベルギー、4000
        • CHC - Groupe Sante ( Site 2041)
      • Liège、ベルギー、4000
        • CHU Liege Sart-Tilman ( Site 2044)
    • Bruxelles-Capitale, Region de
      • Brussels、Bruxelles-Capitale, Region de、ベルギー、1200
        • Saint-Luc UCL ( Site 2042)
    • Hainaut
      • Mons、Hainaut、ベルギー、7000
        • C.I.U. Hopital Ambroise Pare ( Site 2039)
    • Liege
      • Verviers、Liege、ベルギー、4800
        • CHR Verviers ( Site 2035)
    • Oost-Vlaanderen
      • Aalst、Oost-Vlaanderen、ベルギー、9300
        • AZORG Campus Aalst-Moorselbaan ( Site 2038)
      • Ghent、Oost-Vlaanderen、ベルギー、9000
        • AZ Maria Middelares Gent ( Site 2032)
      • Ghent、Oost-Vlaanderen、ベルギー、9000
        • Universitair Ziekenhuis Gent ( Site 2037)
      • Sint-Niklaas、Oost-Vlaanderen、ベルギー、9100
        • AZ Nikolaas ( Site 2031)
    • Vlaams-Brabant
      • Leuven、Vlaams-Brabant、ベルギー、3000
        • UZ Leuven ( Site 2040)
    • West-Vlaanderen
      • Kortrijk、West-Vlaanderen、ベルギー、8500
        • AZ Groeninge ( Site 2036)
    • Greater Poland Voivodeship
      • Poznan、Greater Poland Voivodeship、ポーランド、61-866
        • Wielkopolskie Centrum Onkologii im.M.Sklodowskiej-Curie ( Site 2484)
    • Masovian Voivodeship
      • Siedlce、Masovian Voivodeship、ポーランド、08-110
        • Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2487)
      • Warsaw、Masovian Voivodeship、ポーランド、00-315
        • Szpital Kliniczny im Ks Anny Mazowieckiej ( Site 2481)
    • Podlaskie Voivodeship
      • Bialystok、Podlaskie Voivodeship、ポーランド、15-027
        • Bialostockie Centrum Onkologii ( Site 2483)
    • Silesian Voivodeship
      • Gliwice、Silesian Voivodeship、ポーランド、44-102
        • Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2482)
    • Warmian-Masurian Voivodeship
      • Olsztyn、Warmian-Masurian Voivodeship、ポーランド、10-228
        • Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onko ( Site 2486)
    • Świętokrzyskie Voivodeship
      • Kielce、Świętokrzyskie Voivodeship、ポーランド、25-734
        • Swietokrzyskie Centrum Onkologii. ( Site 2485)
      • Mexico City、メキシコ、06700
        • Hospital Angeles Roma ( Site 1123)
    • Baja California Sur
      • La Paz、Baja California Sur、メキシコ、23040
        • Investigacion Onco Farmaceutica S de RL de CV ( Site 1127)
    • Chiapas
      • Tuxtla Gutiérrez、Chiapas、メキシコ、29090
        • Hospital San Lucas Cardiologica del Sureste ( Site 1122)
    • Mexico City
      • Mexico City、Mexico City、メキシコ、04700
        • Centro Oncologico Internacional. SEDNA ( Site 1121)
      • Mexico City、Mexico City、メキシコ、14080
        • Instituto Nacional de Cancerologia ( Site 1124)
    • Nuevo León
      • Monterrey、Nuevo León、メキシコ、64460
        • Filios Alta Medicina ( Site 1125)
      • Monterrey、Nuevo León、メキシコ、64710
        • I Can Oncology Center SA de CV ( Site 1126)
    • Arkhangelskaya oblast
      • Arkhangelsk、Arkhangelskaya oblast、ロシア、163045
        • Arkhangelsk Clinical Oncological Dispensary ( Site 2637)
    • Baskortostan, Respublika
      • Ufa、Baskortostan, Respublika、ロシア、450054
        • Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 2645)
    • Chelyabinsk Oblast
      • Chelyabinsk、Chelyabinsk Oblast、ロシア、454087
        • Chelyabinsk Regional Clinical Center Oncology and Nuclear Medicine ( Site 2644)
    • Krasnoyarsk Krai
      • Krasnoyarsk、Krasnoyarsk Krai、ロシア、660133
        • Krasnoyarsk Regional Clinical oncology dispensary ( Site 2643)
    • Mordoviya, Respublika
      • Saransk、Mordoviya, Respublika、ロシア、430032
        • National Research Ogarev Mordovia State University ( Site 2648)
    • Moscow
      • Moscow、Moscow、ロシア、115522
        • Fed State Budgetary Inst "N.N. Blokhin Med Center of Oncology" MHRF Dep.of antitumor drug therapy #4 ( Site 2634)
      • Moscow、Moscow、ロシア、125284
        • Moscow Research Oncology Institute named after P.A. Hertsen ( Site 2631)
    • Nizhny Novgorod Oblast
      • Nizhny Novgorod、Nizhny Novgorod Oblast、ロシア、603126
        • Scientific Research Institute of Clinical Oncology "Nizhegorodsky Regional Oncology Dospensary" ( Site 2639)
    • Samara Oblast
      • Samara、Samara Oblast、ロシア、443031
        • Samara Regional Clinical Oncology Center-Chemotherapy Dapartment ( Site 2649)
    • Sankt-Peterburg
      • Saint Petersburg、Sankt-Peterburg、ロシア、197758
        • Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 2636)
    • Tatarstan, Respublika
      • Kazan'、Tatarstan, Respublika、ロシア、420029
        • Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 2646)
    • Tomsk Oblast
      • Tomsk、Tomsk Oblast、ロシア、634028
        • Tomsk Scientific Research Institute of Oncology-Chemotherapy ( Site 2638)
    • Yaroslavl Oblast
      • Yaroslavl、Yaroslavl Oblast、ロシア、150054
        • Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 2641)
    • Anhui
      • Hefei、Anhui、中国、230001
        • Anhui Provincial Hospital-Obstetrics and Gynecology ( Site 4034)
    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100036
        • Beijing Cancer Hospital ( Site 4048)
      • Beijing、Beijing Municipality、中国、100730
        • Peking Union Medical College Hospital ( Site 4036)
    • Chongqing Municipality
      • Chongqing、Chongqing Municipality、中国、400030
        • Chongqing Cancer Hospital ( Site 4040)
    • Fujian
      • Xiamen、Fujian、中国、361003
        • The First Affiliated Hospital of Xiamen University ( Site 4060)
    • Guangdong
      • Guangzhou、Guangdong、中国、510080
        • The First Affiliated Hospital ( Site 4043)
    • Guangxi
      • Nanning、Guangxi、中国、530221
        • Guangxi Medical University Affiliated Tumor Hospital ( Site 4049)
    • Heilongjiang
      • Harbin、Heilongjiang、中国、150081
        • Harbin Medical University Cancer Hospital ( Site 4033)
    • Hubei
      • Wuhan、Hubei、中国、430079
        • Hubei Cancer Hospital ( Site 4059)
    • Hunan
      • Changsha、Hunan、中国、410006
        • Hunan Cancer Hospital ( Site 4050)
      • Changsha、Hunan、中国、410008
        • Xiangya Hospital Central South University ( Site 4035)
    • Jiangsu
      • Nanjing、Jiangsu、中国、210008
        • Nanjing Drum Tower Hospital ( Site 4037)
    • Jiangxi
      • Nanchang、Jiangxi、中国、530021
        • Jiangxi Maternal and Child Health Hospital ( Site 4051)
    • Jilin
      • Changchun、Jilin、中国、130000
        • The First Hospital of Jilin University ( Site 4057)
    • Shaanxi
      • Xi'an、Shaanxi、中国、710061
        • The First Affiliated Hospital of Xi an Jiaotong University ( Site 4045)
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200090
        • Obstetrics and Gynecology Hosp. Fudan University ( Site 4041)
      • Shanghai、Shanghai Municipality、中国、200127
        • Shanghai Renji Hospital Affiliated to Jiao Tong University ( Site 4053)
      • Shanghai、Shanghai Municipality、中国、201204
        • Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 4001)
    • Sichuan
      • Chengdu、Sichuan、中国、610041
        • Sichuan Cancer Hospital. ( Site 4039)
    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国、300000
        • Tianjin Medical University Cancer Institute & Hospital ( Site 4054)
    • Yunnan
      • Kunming、Yunnan、中国、650107
        • Yunnan Province Cancer Hospital-Gynecology Department ( Site 4055)
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310003
        • The First Affiliated Hospital, Zhejiang University-Gynecology ( Site 4002)
      • Hangzhou、Zhejiang、中国、310006
        • Women s Hospital School of Medicine Zhejiang University ( Site 4032)
      • Wenzhou、Zhejiang、中国、325000
        • The First Affiliated Hospital of Wenzhou Medical University ( Site 4056)
      • Changhua、台湾、50006
        • Changhua Christian Hospital ( Site 4095)
      • Taichung、台湾、407
        • Taichung Veterans General Hospital ( Site 4094)
      • Taipei、台湾、10449
        • MacKay Memorial Hospital ( Site 4092)
      • Taipei、台湾、11217
        • Taipei Veterans General Hospital ( Site 4093)
      • Taoyuan、台湾、33305
        • Linkou Chang Gung Memorial Hospital ( Site 4091)
      • Fukuoka、日本、811-1395
        • National Hospital Organization Kyushu Cancer Center ( Site 4193)
      • Niigata、日本、951-8566
        • Niigata Cancer Center Hospital ( Site 4185)
      • Osaka、日本、541-8567
        • Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 4188)
      • Tokyo、日本、160-8582
        • Keio University Hospital ( Site 4191)
      • Tokyo、日本、135-8550
        • Cancer Institute Hospital of JFCR ( Site 4196)
    • Aichi-ken
      • Nagoya、Aichi-ken、日本、464-8681
        • Aichi Cancer Center ( Site 4190)
    • Chiba
      • Kashiwa、Chiba、日本、277-8577
        • National Cancer Center Hospital East ( Site 4197)
    • Ehime
      • Matsuyama、Ehime、日本、791-0280
        • National Hospital Organization Shikoku Cancer Center ( Site 4181)
      • Tōon、Ehime、日本、791-0295
        • Ehime University Hospital ( Site 4187)
    • Fukuoka
      • Kurume、Fukuoka、日本、830-0011
        • Kurume University Hospital ( Site 4186)
    • Gunma
      • Ōta、Gunma、日本、373-8550
        • Gunma Prefectural Cancer Center ( Site 4183)
    • Hokkaido
      • Sapporo、Hokkaido、日本、060-8648
        • Hokkaido University Hospital ( Site 4194)
    • Hyōgo
      • Akashi、Hyōgo、日本、673-8558
        • Hyogo Cancer Center ( Site 4195)
    • Iwate
      • Shiwa-gun、Iwate、日本、028-3695
        • Iwate Medical University Hospital ( Site 4189)
    • Okinawa
      • Ginowan、Okinawa、日本、901-2725
        • University of the Ryukyus Hospital ( Site 4184)
    • Saitama
      • Hidaka、Saitama、日本、350-1298
        • Saitama Medical University International Medical Center ( Site 4182)
    • Shizuoka
      • Suntogun、Shizuoka、日本、411-8777
        • Shizuoka Cancer Center ( Site 4192)
      • Seoul、韓国、03722
        • Severance Hospital Yonsei University Health System ( Site 4062)
      • Seoul、韓国、05505
        • Asan Medical Center ( Site 4061)
      • Seoul、韓国、06351
        • Samsung Medical Center ( Site 4064)
    • Kyonggi-do
      • Goyang-si、Kyonggi-do、韓国、10408
        • National Cancer Center ( Site 4065)
      • Seongnam-si、Kyonggi-do、韓国、13620
        • Seoul National University Bundang Hospital ( Site 4063)

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  • Has a histologically confirmed new diagnosis of Endometrial Carcinoma or Carcinosarcoma (Mixed Mullerian Tumor) and:

    • Has undergone curative intent surgery that included hysterectomy and bilateral salpingo-oophorectomy; and
    • Is at high risk for recurrence following treatment with curative intent surgery, ie: Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) 2009 surgical stage I/II with myometrial invasion of non-endometrioid histology; FIGO 2009 surgical stage I/II with myometrial invasion of any histology with known aberrant p53 expression or p53 mutation; or FIGO (2009) surgical stage III or IVA of any histology.
  • Is disease-free with no evidence of loco-regional disease or distant metastasis post operatively and on imaging.

  • Has not received any radiation or systemic therapy, including immunotherapy, hormonal therapy, or hyperthermic intraperitoneal chemotherapy (HIPEC), in any setting including the neoadjuvant setting for endometrial cancer (EC).

  • Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before randomization.

  • Submission of a tumor tissue sample from current diagnosis of Endometrial Carcinoma or Carcinosarcoma for prospective determination of histology and mismatch repair (MMR) status by central vendor is required for all participants.

  • Has adequate organ function within 7 days of randomization.

Exclusion Criteria:

  • Has recurrent endometrial carcinoma or carcinosarcoma.

  • Has uterine mesenchymal tumor such as an endometrial stromal sarcoma, leiomyosarcoma, or other types of pure sarcomas. Adenosarcomas are also not allowed.

  • Has FIGO (2009) Surgical Stage I/II EC of endometrioid histology without a known aberrant p53 expression or p53 mutation.

  • Is known to have a deoxyribonucleic acid (DNA) polymerase epsilon catalytic subunit A (POLE) mutation.

  • Has FIGO Stage IVB disease of any histology even if there is no evidence of disease after surgery.

  • Has residual tumor whether measurable or non-measurable after surgery.

  • Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.

    • Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, or other in situ cancers.
  • Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1), anti-programmed cell death receptor ligand 1 (PD-L1), or anti-programmed cell death receptor ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).

  • Has received a live vaccine within 30 days before the first dose of study intervention.

    • Note: killed vaccines are allowed.
  • Has a known intolerance to study intervention (or any of the excipients).

  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.

    • Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
  • Has any contraindication to the use of carboplatin or paclitaxel.

  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention.

  • Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.

  • Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.

  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.

  • Has an active infection requiring systemic therapy.

  • Has a known history of HIV infection.

  • Has a known history of Hepatitis B or known active Hepatitis C virus infection.

  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.

  • Has had an allogenic tissue/solid organ transplant.

  • Has not recovered adequately from surgery and/or any complications from the surgery.

  • Is breastfeeding.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Pembrolizumab + Chemotherapy

Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of pembrolizumab, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation.

IV infusion

他の名前:
  • MK-3475
  • キイトルーダ®

IV infusion

IV infusion

IV infusion docetaxel 75 mg/m^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.

Cisplatin 75 mg/m^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.

他の名前:
  • プラチノール®
  • Platinol®-AQ

≥4500 cGY given according to local practice, at the discretion of the investigator

If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29

他の名前:
  • プラチノール®
  • Platinol®-AQ

Given according to local practice, at the discretion of the investigator

他の名前:
  • 内部放射線療法
プラセボコンパレーター:Placebo + Chemotherapy

Participants receive placebo to pembrolizumab intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of placebo, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation.

IV infusion

IV infusion

IV infusion docetaxel 75 mg/m^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.

Cisplatin 75 mg/m^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.

他の名前:
  • プラチノール®
  • Platinol®-AQ

≥4500 cGY given according to local practice, at the discretion of the investigator

If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29

他の名前:
  • プラチノール®
  • Platinol®-AQ

Given according to local practice, at the discretion of the investigator

他の名前:
  • 内部放射線療法

IV infusion

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence
時間枠:Up to approximately 42 months

DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence, will be presented.

Up to approximately 42 months
Overall Survival (OS)
時間枠:Up to approximately 54 months

OS is defined as the time from randomization to death due to any cause.

Up to approximately 54 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Disease-Free Survival (DFS) as Assessed Radiographically by Blinded Independent Central Review (BICR) or by Histopathologic Confirmation of Suspected Disease Recurrence
時間枠:Up to approximately 42 months

DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by BICR or by histopathologic confirmation of suspected disease recurrence, will be presented.

Up to approximately 42 months
Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Combined Positivity Score (CPS)-Determined Programmed Cell Death 1 Ligand 1 (PD-L1) Status
時間枠:Up to approximately 42 months

DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by CPS-determined PD-L1 status will be presented.

Up to approximately 42 months
Overall Survival (OS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Combined Positivity Score (CPS)-Determined Programmed Cell Death 1 Ligand 1 (PD-L1) Status
時間枠:Up to approximately 54 months

OS is defined as the time from randomization to death due to any cause. The OS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by CPS-determined PD-L1 status will be presented.

Up to approximately 54 months
Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Tumor Mutation Burden (TMB) Status
時間枠:Up to approximately 42 months

DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by tumor mutation burden (TMB) status, will be presented.

Up to approximately 42 months
Overall Survival (OS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Tumor Mutation Burden (TMB) Status
時間枠:Up to approximately 54 months

OS is defined as the time from randomization to death due to any cause. The OS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by tumor mutation burden (TMB) status will be presented.

Up to approximately 54 months
Number of Participants Who Experience One or More Adverse Events (AEs)
時間枠:Up to approximately 54 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented.

Up to approximately 54 months
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
時間枠:Up to approximately 52 weeks

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented.

Up to approximately 52 weeks
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (QoL) Score
時間枠:Baseline and up to approximately 54 months

The EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. Participant responses to questions 29 ("How would you rate your overall health during the past week?") and 30 ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). A higher score indicates a better overall health/quality of life status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined scores will be presented.

Baseline and up to approximately 54 months
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Physical Function Score
時間枠:Baseline and up to approximately 54 months

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=not at all to 4=very much). A higher score indicates a better quality of life. The change from baseline in physical function (EORTC QLQ-C30 Items 1-5) score will be presented.

Baseline and up to approximately 54 months
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Endometrial Cancer (EORTC QLQ-EN24) Score
時間枠:Baseline and up to approximately 54 months

The EORTC-QLQ-EN24 is a 24-item questionnaire developed to be used in conjunction with the EORTC-QLQ-C30 to assess the quality of life of endometrial cancer patients. Participant responses are scored on a 4-point scale (1=not at all to 4=very much). A higher score indicates a better quality of life. The change from baseline in EORTC QLQ-E24 score will be presented.

Baseline and up to approximately 54 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Medical Director、Merck Sharp & Dohme LLC

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年1月10日

一次修了 (推定)

2026年11月20日

研究の完了 (推定)

2026年11月20日

試験登録日

最初に提出

2020年11月12日

QC基準を満たした最初の提出物

2020年11月12日

最初の投稿 (実際)

2020年11月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月18日

QC基準を満たした最後の更新が送信されました

2026年9月17日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する